SABS
SAB Biotherapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Strong Buy
1.1 / 5
11 analysts
$3.58
$-0.06 (-1.65%)
Target:
$11.18
(212.3%)
Sign in to add SABS to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $296.68M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.96 |
| EPS (TTM) | $-0.58 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -0.32% |
| Debt/Equity | 2.72 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $11.18 |
| Analysts | 11 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 67.3 |
| Beta | 0.55 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.60 |
| 52-Week Low | $1.72 |
| 50-Day Avg | $3.69 |
| 200-Day Avg | $3.58 |
| Avg Volume | 897.6K |
| Volume | 179.3K |
Performance Analysis
BULLISHSABS shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 38% of its 52-week range.
+
RSI at 67.3 shows positive momentum.
~
Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+
Wall Street consensus is "Strong Buy" from 11 analysts.
+
Average analyst target of $11.18 implies 212.3% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:30 UTC
Back to Screener Export Report